1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Systematic review of stereotactic ablative radiotherapy (SABR)/stereotactic body radiation therapy (SBRT) for treatment of high-risk patients with stage I non-small cell lung cancer
    Review

    Wolf, A.; Loo, B. W. Jr; Mak, R. H.; Liptay, M.; Pettiford, B.; Rocco, G.; Lanuti, M.; Merritt, R. E.; Keshavarz, H.; Suh, R. D.; more...
    Seminars in Thoracic and Cardiovascular Surgery (2025)

    Fulltext@MSK | Save
  • Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: A randomized phase 3 trial
    Journal Article

    Kopetz, S.; Yoshino, T.; Van Cutsem, E.; Eng, C.; Kim, T. W.; Wasan, H. S.; Desai, J.; Ciardiello, F.; Yaeger, R.; Maughan, T. S.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Characteristics of prostate cancer patients seeking integrative medicine
    Research Letter

    Silberlust, J.; Lampson, K.; Han, K.; Li, S. Q.; Mao, J. J.; Liou, K. T.
    Journal of the American Geriatrics Society (2025)

    Fulltext@MSK | Save
  • Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomes
    Journal Article

    Perrot, A.; Facon, T.; Plesner, T.; Usmani, S. Z.; Kumar, S.; Bahlis, N. J.; Hulin, C.; Orlowski, R. Z.; Nahi, H.; Mollee, P.; more...
    European Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) in a diverse cancer sample
    Journal Article

    Mead-Harvey, C.; Basch, E.; Rogak, L. J.; Langlais, B. T.; Thanarajasingam, G.; Ginos, B. F.; Lee, M. K.; Yee, C.; Mitchell, S. A.; Minasian, L. M.; more...
    Clinical Trials (2025)

    Fulltext@MSK | Save
  • Management approaches for primary hepatic lymphoma: 10 year institutional experience with comprehensive literature review
    Journal Article

    Ma, J.; Daou, R.; Bou Eid, J.; Fregonese, B.; El-Khoury, J.; Wijetunga, N. A.; Imber, B. S.; Yahalom, J.; Hajj, C.
    Frontiers in Oncology (2025)

    Fulltext@MSK | Save
  • Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
    Journal Article

    Bedard, P. L.; Jhaveri, K. L.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; more...
    European Journal of Cancer (2025)

    Fulltext@MSK | Save
  • Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma
    Journal Article

    Lauer, U. M.; Awada, A.; Postel-Vinay, S.; Shapiro, G. I.; Thieblemont, C.; Piha-Paul, S. A.; Paik, P. K.; Shepard, D. R.; Docampo, L. I.; Galot, R.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease
    Research Letter

    Goyal, G.; Reiner, A. S.; Bossert, D.; Sigler, A. M.; Lacouture, M. E.; Rotemberg, V.; Francis, J. H.; Go, R. S.; Rampal, R. K.; Diamond, E. L.
    Blood (2025)

    Fulltext@MSK | Save
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
    Research Letter

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A.; Sallman, D.; Patel, M.; Stevens, D.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Leukemia (2025)

    Fulltext@MSK | Save